- Home
- Products
- Services
- Resources
- About Us
- News
- Contact
Views: 0 Author: Site Editor Publish Time: 2026-08-21 Origin: Site
Prostate-specific membrane antigen, commonly known as PSMA, has become an important biomarker in prostate cancer research, pathology, and targeted diagnostic development. Its value is closely related to its cell-surface location, increased expression in many prostate cancer tissues, and relevance to both tissue-based and molecular imaging applications.
PSMA is a protein encoded by the FOLH1 gene. It is also known as folate hydrolase 1 and glutamate carboxypeptidase II. According to the NCBI FOLH1 gene record, FOLH1 encodes a membrane-associated protein with a large extracellular domain.
For pathology and assay development laboratories, understanding PSMA biology is an important first step before selecting antibodies, establishing staining conditions, or evaluating PSMA IHC reference materials. This article reviews the structure and expression of PSMA in prostate cancer and explains its diagnostic significance in tissue-based applications.
PSMA is a cell-surface protein encoded by the FOLH1 gene.
It is a type II transmembrane glycoprotein with a large extracellular domain.
PSMA expression is frequently increased in prostate cancer, although staining intensity and distribution may vary between tissues and disease settings.
PSMA is not completely exclusive to prostate cancer. It may also be detected in the tumor-associated vasculature of some non-prostatic tumors.
PSMA IHC helps visualize PSMA protein expression in tissue sections, but results should be interpreted together with morphology, clinical information, and other relevant markers.
Positive and negative PSMA IHC reference standards can help laboratories evaluate staining specificity, background, signal intensity, and reproducibility.
PSMA is a type II transmembrane glycoprotein. It contains a short intracellular region, a transmembrane segment, and a large extracellular domain. This structural organization allows PSMA to remain associated with the cell membrane while presenting a substantial extracellular region for molecular recognition.
The protein structure and genomic localization of PSMA were described in early molecular studies, including research published in Genomics. In laboratory applications, the extracellular domain is particularly relevant because many antibodies and targeted molecules recognize epitopes located outside the cell.
The name “prostate-specific membrane antigen” reflects the protein’s original association with prostate tissue. However, the term should not be interpreted to mean that PSMA is expressed only by prostate cells. Its expression pattern depends on the tissue type, disease context, cellular location, and analytical method used.
PSMA expression is commonly increased in prostate cancer compared with normal prostate tissue. Research has reported PSMA upregulation in prostate cancer cells and has also described changes in expression associated with disease progression. However, PSMA expression is not uniform across all prostate cancer samples.
Differences may be observed between:
Primary and advanced prostate cancer tissues
Different tumor regions within the same specimen
Tumor cells and surrounding non-tumor tissue
Patients with different disease characteristics
Samples processed using different fixation and staining methods
These variations are important for IHC assay development. A tissue sample may show strong staining in one area and weaker or absent staining in another. Therefore, PSMA interpretation should consider both staining intensity and staining distribution.
Studies evaluating PSMA expression by immunohistochemistry have reported membranous and cytoplasmic staining patterns in prostate cancer tissues. The proportion of positive cells and the strength of staining may vary according to tumor type, grade, and assay conditions. A study of PSMA expression patterns in prostate cancer is available through PubMed.
For this reason, a single positive or negative observation should not be interpreted without considering tissue morphology and the performance of the complete staining workflow.
No. PSMA is strongly associated with prostate cancer, but it is not absolutely restricted to prostate-derived tumor cells.
PSMA expression has also been reported in the tumor-associated neovasculature of several non-prostatic solid tumors. In these cases, the staining may be related to endothelial cells in newly formed tumor blood vessels rather than to the tumor cells themselves. This distinction is important because cellular location and tissue morphology can influence the interpretation of an IHC result.
Research on PSMA expression in tumor-associated vasculature has been summarized in studies such as this PubMed publication. The practical implication is that PSMA staining should be evaluated in context. Laboratories should consider:
Which cells are stained
Whether the signal is membranous or cytoplasmic
The distribution of positive cells
The surrounding tissue morphology
The staining pattern in the negative control
The performance of the antibody and detection system
This contextual approach is especially important when PSMA IHC is used to support research on tumor classification, biomarker expression, or assay development.
PSMA has several characteristics that make it valuable as a biomarker.
First, it is located on the cell surface. This makes it accessible to antibodies and other targeted molecules. Second, its expression is frequently increased in prostate cancer tissues. Third, its expression can provide information about the presence and distribution of a PSMA-associated signal within a tissue section.
In diagnostic pathology research, PSMA IHC may support the evaluation of prostate-related lesions when used together with morphology and other immunohistochemical markers. It can help researchers study the presence, localization, and relative intensity of PSMA protein expression.
However, PSMA positivity alone should not be treated as an independent diagnosis. IHC results are influenced by tissue quality, fixation, antigen retrieval, antibody selection, detection chemistry, and interpretation criteria. A reliable result therefore depends not only on the biological relevance of the marker but also on the quality and consistency of the assay.
PSMA is also relevant to targeted imaging and therapeutic research. These applications are related to the same cell-surface target but should be distinguished from PSMA IHC. Tissue staining provides information about protein expression in a tissue sample; it does not by itself establish eligibility for a specific imaging or treatment procedure.
PSMA immunohistochemistry uses an antibody-based staining method to visualize PSMA expression in tissue sections. The resulting staining pattern can help laboratories assess:
Whether PSMA-associated signal is present
Which cells or tissue structures show staining
The relative intensity of the signal
The distribution of positive and negative areas
The level of background staining
The reproducibility of the staining result
The final staining pattern is affected by multiple parts of the workflow. These may include fixation time, paraffin processing, section quality, antigen retrieval, antibody concentration, incubation conditions, detection chemistry, and signal interpretation.
As a result, the same target may produce different staining performance when tested under different laboratory conditions. This is one reason why laboratories need well-defined control materials during assay development and routine quality control.
PSMA IHC reference standards provide a defined material for evaluating assay performance. A suitable standard can help laboratories compare positive and negative staining behavior under controlled testing conditions.
A combined positive and negative format can be particularly useful because it allows the two staining responses to be assessed during the same run. This supports evaluation of:
Antibody specificity
Positive signal intensity
Negative staining behavior
Background staining
Staining consistency
Repeatability between runs
Differences between assay conditions
For laboratories developing or validating a PSMA IHC workflow, reference standards can help identify whether an unexpected result is related to the antibody, tissue processing, antigen retrieval, detection system, or interpretation step.
CB-Gene provides IHC reference standards for laboratory research and assay-related applications. The specific format and control design should be selected according to the intended workflow, testing stage, and validation requirements.
When assessing a PSMA IHC control, laboratories should review both the biological staining pattern and the technical performance of the assay.
Important evaluation points may include:
The positive control should demonstrate a clear and interpretable PSMA-associated signal. The expected intensity may depend on the tissue material, antibody, detection system, and laboratory protocol.
The negative control should help laboratories assess whether non-specific staining or excessive background is present. A clean negative area makes it easier to distinguish target-associated signal from technical artifacts.
The location and distribution of staining are important. Laboratories should examine whether the signal appears in the expected cell population or tissue structure and whether the pattern is consistent across the control material.
A useful control should support repeat testing. Consistent results across different runs can help laboratories monitor workflow stability and identify changes in assay performance.
Control material should be evaluated in the context of the laboratory’s staining platform, sectioning method, antibody protocol, and interpretation criteria. Controls are most useful when their format is appropriate for the assay being developed or monitored.
For laboratories that require a target-specific format or a customized control design, CB-Gene also offers customized IHC standards for research and assay development needs.
PSMA is a membrane-associated protein encoded by FOLH1 and is frequently expressed at increased levels in prostate cancer. Its cell-surface location and expression pattern make it an important biomarker for prostate cancer research, pathology applications, and targeted diagnostic development.
At the same time, PSMA is not completely exclusive to prostate cancer, and expression may vary between samples and tissue compartments. Reliable interpretation therefore requires attention to morphology, staining localization, signal intensity, assay conditions, and control performance.
For laboratories working with PSMA immunohistochemistry, well-defined positive and negative reference standards can support assay development, validation, troubleshooting, and routine quality monitoring.
Building or validating a PSMA IHC workflow?
Explore CB-Gene’s IHC reference standards and customized IHC standard services for assay development, validation, and routine quality control.
PSMA stands for prostate-specific membrane antigen. It is a cell-surface protein associated with the FOLH1 gene and is frequently studied in prostate cancer research.
FOLH1 is the gene that encodes PSMA. The protein is also known as folate hydrolase 1 and glutamate carboxypeptidase II.
No. PSMA is strongly associated with prostate cancer, but it may also be expressed in the tumor-associated vasculature of some non-prostatic solid tumors. Tissue morphology and staining location should therefore be considered during interpretation.
PSMA IHC visualizes PSMA protein expression in tissue sections. It can help evaluate staining presence, localization, intensity, and distribution under a defined antibody and detection workflow.
Positive and negative controls help laboratories evaluate staining specificity, background, signal intensity, and repeatability. A combined positive and negative control format can allow both responses to be assessed in the same staining run.
PSMA IHC should not generally be interpreted as a standalone diagnostic test. Results should be assessed together with tissue morphology, clinical context, other relevant markers, and the validated performance characteristics of the assay.
